IDiyas

For the Inventor, By the Inventor

New Palestine, IN, United States of America

David Andrew Coates

USPTO Granted Patents = 33 

 

 

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 116(Granted Patents)


Location History:

  • West Lafayette, IN (US) (2003 - 2006)
  • Indianapolis, IN (US) (2010 - 2020)
  • New Palestine, IN (US) (2017 - 2024)

Company Filing History:

goldMedal28 out of 4,442 
 
Eli Lilly and Company
 patents
silverMedal2 out of 2,538 
 
Warner-lambert Company
 patents
bronzeMedal1 out of 10 
 
Eli Lilly Company
 patents
4. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...
Loading Chart...
Loading Chart...
33 patents (USPTO):
1. 12486249 - SSTR4 agonist salts (2025-12-02),
2. 12252491 - IL-17A inhibitors (2025-03-18),
3. 12071423 - Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate (2024-08-27),
4. 11999722 - Disubstituted pyrazole compounds (2024-06-04),
5. 11834435 - SSTR4 agonist salts (2023-12-05),
6. 11827618 - Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate (2023-11-28),
7. 11746115 - Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one (2023-09-05),
8. 11655242 - Glucagon-like peptide1 receptor agonists (2023-05-23),
9. 11498915 - TrkA Inhibitor (2022-11-15),
10. 11124500 - Disubstituted pyrazole compounds (2021-09-21),
11. 11066386 - CGRP receptor antagonists (2021-07-20),
12. 10968214 - KRas G12C inhibitors (2021-04-06),
13. 10934280 - Condensed thiophene derivatives useful as NaPi-IIb inhibitors (2021-03-02),
14. 10793552 - Amino pyrimidine ssao inhibitors (2020-10-06),
15. 10787460 - (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 (2020-09-29),

Title: **David Andrew Coates: Innovator in Pharmaceutical Development**

Introduction

David Andrew Coates, a prolific inventor based in New Palestine, Indiana, holds an impressive portfolio of 28 patents. His contributions significantly advance pharmaceutical processes, particularly in the preparation of complex chemical compounds essential for various treatments.

Latest Patents

David's most recent patents include innovative processes and intermediates for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate. This patent details a method of producing tablets containing various dosages, including 25 mg, 50 mg, 100 mg, or 200 mg of the free base equivalent. Additionally, he has developed disubstituted pyrazole compounds intended for treating metabolic conditions like type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Career Highlights

David is currently a key player at Eli Lilly and Company, a leading global healthcare firm. His work focuses on the advancement of novel therapeutic formulations that deliver substantial benefits to patients. His extensive experience has positioned him as a valuable asset within the pharmaceutical industry.

Collaborations

Throughout his career, David has collaborated with notable colleagues such as Steven Marc Massey and Craig Daniel Wolfangel. These partnerships enhance the innovative capacity and efficiency of developing groundbreaking solutions in pharmaceutical research.

Conclusion

David Andrew Coates exemplifies the spirit of innovation within the pharmaceutical industry. His dedication to advancing healthcare through novel inventions and collaborative research continues to make a significant impact on the treatment of critical metabolic diseases. With his impressive portfolio and ongoing projects, he remains a leader in pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…